Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomesArticle Published on 2022-11-122022-11-15 Journal: Biochemical and Biophysical Research Communication [Category] SARS, 변종, 치료제, [키워드] acute respiratory syndrome Adaptability Antiviral approved circulating coronavirus correlation COVID-19 cases COVID-19 pandemic develop drug resistance FDA highest hotspot intracellular protein Like M pro main protease Mild-to-moderate mutant Mutation mutations Nirmatrelvir offer omicron predicted Probability protease Protein design reported residue residues resistance resistance mutations robust SARS-CoV-2 SARS-CoV-2 lineage signature Signatures of adaptation. Surveillance unique variant Variation variations viral adaptation viral genome viruses [DOI] 10.1016/j.bbrc.2022.09.010 PMC 바로가기
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sitesArticle Published on 2022-10-122022-11-15 Journal: Cell Host & Microbe [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] 3CL 3CL pro 3CL Protease approach biological property clinically conserved Coronaviruses COVID-19 deep mutational scanning develop drug resistance functional identify inhibitor inhibitors Mutation Nirmatrelvir protease protease inhibitors Protein residue reveal SARS-CoV-2 single mutant subset target therapeutic target Tolerance virus viruses [DOI] 10.1016/j.chom.2022.08.003 PMC 바로가기
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyArticle Published on 2022-10-082022-11-15 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Abstract Admission age ambulatory patient Analysis Antiviral antiviral drug authority B.1.1.529 Case-control Charlson Comorbidity Index China Chinese clinical effectiveness Cohort Community Control COVID-19 outpatient Cox regression death Diagnosis diagnosis of SARS-CoV-2 Disease progression dominant Effectiveness glomerular filtration rate hazard Hong Kong hospitalisation HRs identify in both group In-hospital In-hospital death Infection intensive care Invasive mechanical ventilation less Logistic regression lower risk material median molnupiravir Mortality Nirmatrelvir non-hospitalised Odds ratio Older older patients outcome Outpatient Patient patients with COVID-19 primary analysis reduced risk Region Registered retrospective cohort risk Ritonavir SARS-CoV-2 SARS-COV-2 infection sensitivity analysis Sex supported the SARS-CoV-2 translation used data vaccination variant [DOI] 10.1016/S0140-6736(22)01586-0 PMC 바로가기
A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a CaseCase Reports Published on 2022-10-052023-07-10 Journal: Journal of the American Society for Mass Spectrome [Category] COVID19(2023년), [키워드] COVID-19 Liquid chromatography mass spectrometry Nirmatrelvir Ritonavir [DOI] 10.1021/jasms.2c00204 [Article Type] Case Reports
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surgeArticle Published on 2022-10-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] Administered age antiviral agent clinical trials conducted coronavirus COVID-19 COVID-19 diagnosis death diagnosed with COVID-19 Effectiveness Follow-up Healthcare systems Hospitalization kidney transplant recipients knowledge males mild-to-moderate disease molnupiravir monoclonal antibody morbidity and mortality Nirmatrelvir omicron organ Outpatient Patient Rate recipient reduced reducing retrospective SARS-CoV-2 SARS-CoV-2 pandemic single-center solid organ transplant Sotrovimab therapy [DOI] 10.1111/ajt.17098 PMC 바로가기
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] 치료제, [키워드] 24 hour adjusted Administered adverse event adverse outcome assessments Chronic kidney disease clearance coronavirus disease COVID-19 decrease dose dose reduction Effect eliminated evaluated exhibited geometric geometric mean ratio glomerular filtration rate group increased risk kidney laboratory measurements Mild mild in severity moderate Nirmatrelvir oral participant Patient patients with moderate pharmacokinetics Phase I plasma plasma concentration positively correlated progression reducing renal renal function renal impairment risk Ritonavir severe disease severe renal impairment systemic Tolerability vital signs [DOI] 10.1002/cpt.2688 PMC 바로가기
First-generation oral antivirals against SARS-CoV-2Review article Published on 2022-09-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Antiviral antiviral agent Clinical practice clinical trials Compliance content coronavirus COVID-19 death drug drug-drug interaction early administration Efficacy Emergency use authorization Frequency Google Scholar high risk Hospitalization Hospitalized Immunosuppressed include individual ingestion Mild-to-moderate molnupiravir Nirmatrelvir objective oral Patient persistence progression reduced reference Regulatory required risk reduction Ritonavir SARS-CoV-2 Source Toxicity Treatment website [DOI] 10.1016/j.cmi.2022.04.015 [Article Type] Review article
Hospitalization as an outcome in ambulatory COVID-19 trials—not applicable in every settingDiscussion Published on 2022-09-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] clinical trials COVID-19 molnupiravir Nirmatrelvir outcome Remdesivir SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.05.026 [Article Type] Discussion
New Variants of SARS-CoV-2 and Next Generation of COVID-19 TreatmentsArticle Published on 2022-09-012023-07-09 Journal: Journal of clinical pharmacology [Category] COVID19(2023년), [키워드] antivirals COVID-19 molnupiravir Nirmatrelvir omicron Remdesivir [DOI] 10.1002/jcph.2067
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeArticle Published on 2022-09-012022-10-06 Journal: The New England Journal of Medicine [Category] SARS, 변종, 진단, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome adjusted hazard ratio Adults age association B.1.1.529 B.1.617.2 benefit conditions coronavirus covariate death Effectiveness Efficacy eligibility criteria eligible Hospitalization Nirmatrelvir no evidence of Older omicron outcome Patient Protease inhibitor receive Regression model SARS-CoV-2 SARS-CoV-2 immunity service severe coronavirus disease shown significantly lower sociodemographic factors study period therapy treated patient Treatment untreated patient variant was used were assessed [DOI] 10.1056/NEJMoa2204919 PMC 바로가기 [Article Type] Article